Human leukemia patients have shown continual activation of STAT5 by JAK mutations, BCL-ABL chimeric oncoproteins, TEL-JAK2 fusion proteins, or FLT-ITD mutations [12,26,27,28,29,30]. This evidence concerns the gene STAT5A and leukemia.